Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
DOI:
https://doi.org/10.2340/actadv.v103.5243Keywords:
atopic dermatitis, daily practice, upadacitinib, patient-reported outcome measure, Janus kinase inhibitorAbstract
Clinical trials showed that upadacitinib, a selective Janus kinase-1 inhibitor, is effective for treatment of moderate-to-severe atopic dermatitis. However, daily practice studies are limited. This multicentre prospective study evaluated the effectiveness of 16 weeks of upadacitinib treatment for moderate-to-severe atopic dermatitis in adult patients, including those with previous inadequate response to dupilumab and/or baricitinib, in daily practice. A total of 47 patients from the Dutch BioDay registry treated with upadacitinib were included. Patients were evaluated at baseline, and after 4, 8 and 16 weeks of treatment. Effectiveness was assessed by clinician- and patient-reported outcome measurements. Safety was assessed by adverse events and laboratory assessments. Overall, the probabilities (95% confidence intervals) of achieving Eczema Area and Severity Index ≤ 7 and Numerical Rating Scale – pruritus ≤ 4 were 73.0% (53.7–86.3) and 69.4% (48.7–84.4), respectively. The effectiveness of upadacitinib was comparable in patients with inadequate response to dupilumab and/or baricitinib and in patients who were naïve for these treatments or who had stopped such treatments due to adverse events. Fourteen (29.8%) patients discontinued upadacitinib due to ineffectiveness, adverse events or both (8.5%, 14.9% and 6.4%, respectively). Most frequently reported adverse events were acneiform eruptions (n = 10, 21.3%), herpes simplex (n = 6, 12.8%), nausea and airway infections (both n = 4, 8.5%). In conclusion, upadacitinib is an effective treatment for patients with moderate-to-severe atopic dermatitis, including those with previous inadequate response to dupilumab and/or baricitinib treatment.
Downloads
References
Weidinger S, Novak N. Atopic dermatitis. Lancet 2016; 387: 1109-1122.
https://doi.org/10.1016/S0140-6736(15)00149-X DOI: https://doi.org/10.1016/S0140-6736(15)00149-X
Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy 2018; 73: 1284-1293.
https://doi.org/10.1111/all.13401 DOI: https://doi.org/10.1111/all.13401
Pereyra-Rodriguez JJ, Alcantara-Luna S, Dominguez-Cruz J, Galan-Gutierrez M, Ruiz-Villaverde R, Vilar-Palomo S, et al. Short-term effectiveness and safety of biologics and small molecule drugs for moderate to severe atopic dermatitis: a systematic review and network meta-analysis. Life 2021; 11: 927.
https://doi.org/10.3390/life11090927 DOI: https://doi.org/10.3390/life11090927
Domaingroup Allergy and Eczema and Association for Atopic Dermatitis (VMCE), the Netherlands. Dupilumab (opinion). Published April 2018 [accessed August 4, 2022]. Available from https://nvdv.nl/professionals/nvdv/standpunten-en-leidraden/introductie-van-dupilumab-voor-ernstig-constitutioneel-eczeem-ce-standpunt
Miniotti M, Lazzarin G, Ortoncelli M, Mastorino L, Ribero S, Leombruni P. Impact on health-related quality of life and symptoms of anxiety and depression after 32 weeks of dupilumab treatment for moderate-to-severe atopic dermatitis. Dermatol Ther 2022; 35: e15407.
https://doi.org/10.1111/dth.15407 DOI: https://doi.org/10.1111/dth.15407
Domaingroup Allergy and Eczema and Association for Atopic Dermatitis (VMCE), the Netherlands. Baricitinib (opinion). Published December 2020 [accessed August 4, 2022]. Available from https://nvdv.nl/professionals/nvdv/standpunten-en-leidraden/baricitinib-standpunt
He Helen, Guttman-Yasky E. JAK inhibitors for atopic dermatitis: an update. Am J Clin Derm 2019; 20: 181-192.
https://doi.org/10.1007/s40257-018-0413-2 DOI: https://doi.org/10.1007/s40257-018-0413-2
Domaingroup Allergy and Eczema and Association for Atopic Dermatitis (VMCE), the Netherlands. Upadacitinib (opinion). Published October 2021 [accessed August 4, 2022] Available from https://nvdv.nl/nvdv/standpunten-en-leidraden/upadacitinib-standpunt
Nezamololama N, Fieldhouse K, Metzger K, Gooderham M. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib. Drugs in Context 2020; 9: 5-8.
https://doi.org/10.7573/dic.2020-8-5 DOI: https://doi.org/10.7573/dic.2020-8-5
Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 2021; 397: 2151-2168.
https://doi.org/10.1016/S0140-6736(21)00588-2 DOI: https://doi.org/10.1016/S0140-6736(21)00588-2
Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2021; 397: 2169-2218.
https://doi.org/10.1016/S0140-6736(21)00589-4 DOI: https://doi.org/10.1016/S0140-6736(21)00589-4
Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, de Bruin-Weller M, Barbarot S, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis a randomized clinical trial. JAMA 2021; 157: 1047-1055.
https://doi.org/10.1001/jamadermatol.2021.3023 DOI: https://doi.org/10.1001/jamadermatol.2021.3023
Napolitano N, Fabbrocini G, Genco L, Martora F, Potestio L, Patruno C. Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real-life experience. J Eur Acad Dermatol Venereol 2022; 36: 1497-1498.
https://doi.org/10.1111/jdv.18137 DOI: https://doi.org/10.1111/jdv.18137
Feraru G, Nevet MJ, Samuelov L, Hodak E, Avitan-Hersh E, Ziv M, et al. Real-life experience of upadacitinib for the treatment of adult patients with moderate-to-severe atopic dermatitis - a case series. J Eur Acad Dermatol Venereol 2022; 36: e832-e833.
https://doi.org/10.1111/jdv.18311 DOI: https://doi.org/10.1111/jdv.18311
Pereyra-Rodriguez JJ, Herranz P, Figueras-Nart I, Perez B, Elosua M, Munera-Campos M, et al. Treatment of severe atopic dermatitis with upadacitinib in real clinical practice. Short-term efficacy and safety results. J Investig Allergol Clin Immunol 2022; Jun 2. [Online ahead of print].
https://doi.org/10.18176/jiaci.0831 DOI: https://doi.org/10.18176/jiaci.0831
Chiricozzi A, Gori N, Narcisi A, Balato A, Gambardella A, Ortoncelli M, et al. Effectiveness and safety of upadacitinib in the treatment of moderate‑severe atopic dermatitis: a multicentric, prospective, real‑world, cohort study. Drugs in R&D 2022; 22: 245-252.
https://doi.org/10.1007/s40268-022-00396-1 DOI: https://doi.org/10.1007/s40268-022-00396-1
Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol 2015; 172: 1353-1357.
https://doi.org/10.1111/bjd.13662 DOI: https://doi.org/10.1111/bjd.13662
Futamara M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. JAAD 2016; 74: 288-294.
https://doi.org/10.1016/j.jaad.2015.09.062 DOI: https://doi.org/10.1016/j.jaad.2015.09.062
Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol 2012; 92: 502-507.
https://doi.org/10.2340/00015555-1246 DOI: https://doi.org/10.2340/00015555-1246
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
https://doi.org/10.1111/j.1365-2230.1994.tb01167.x DOI: https://doi.org/10.1111/j.1365-2230.1994.tb01167.x
Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol 2004; 140: 1513-1519.
https://doi.org/10.1001/archderm.140.12.1513 DOI: https://doi.org/10.1001/archderm.140.12.1513
Griffiths C, de Bruin-Weller M, Deleuran M, Concetta Fargnoli M, Staumont-Sallé D, et al. Dupilumab in adults with moderate-to-severe atopic dermatitis and prior use of systemic non-steroidal immunosuppressants: analysis of four phase 3 trials. Dermatol Ther 2021; 11: 1357-1372.
https://doi.org/10.1007/s13555-021-00558-0 DOI: https://doi.org/10.1007/s13555-021-00558-0
Pariser DM, Simpson EL, Gadkari A, Bieber T, Margolis DJ, Brown M, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin 2020; 36: 367-376.
https://doi.org/10.1080/03007995.2019.1699516 DOI: https://doi.org/10.1080/03007995.2019.1699516
De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, et al. Treat-to-target in atopic dermatitis: an International Consensus on a set of core decision points for systemic therapies. Acta Derm Venereol 2021; 17: 101-102.
https://doi.org/10.2340/00015555-3751 DOI: https://doi.org/10.2340/00015555-3751
Donders ART, Van der Heijden GJMG, Stijnen T, Moons KGM. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 2006; 59: 1087-1091.
https://doi.org/10.1016/j.jclinepi.2006.01.014 DOI: https://doi.org/10.1016/j.jclinepi.2006.01.014
Graham JW, Olchowski AE, Gilreath TD. How many imputations are really needed? Some practical clarifications of multiple imputation theory. Prev Sci 2007; 8: 206-213.
https://doi.org/10.1007/s11121-007-0070-9 DOI: https://doi.org/10.1007/s11121-007-0070-9
Robitzsch A, Grund S. Miceadds: Some Additional Multiple Imputation Functions, Especially for 'mice'. R package version 3.13-1. 2022. [Accessed 17 August 2022] Available from: https://cran.r-project.org/web/packages/miceadds/index.html.
RStudio Team. RStudio: Integrated Development for R. RStudio, PBC, Boston, MA. 2020. [Accessed 17 August 2022] Available from: URL:http://www.rstudio.com/.
Guttman-Yassky E, Thyssen JP, Silverberg JI, Papp KA, Paller AS, Weidinger S, et al. Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies. J Allergy Clin Immunol 2023; 151: 172-181.
https://doi.org/10.1016/j.jaci.2022.09.023 DOI: https://doi.org/10.1016/j.jaci.2022.09.023
Additional Files
Published
How to Cite
License
Copyright (c) 2023 Celeste M. Boesjes, Liana F. van der Gang, Nicolaas P.A. Zuithoff, Daphne S. Bakker, Lotte S. Spekhorst, Inge Haeck, Marijke Kamsteeg, Marlies de Graaf, Marjolein S. de Bruin-Weller
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
